Several clinical studies on inhibitors targeting CDK4 and CDK6 in pRb-positive tumors (breast cancer, melanoma, liposarcoma, and so on) have shown that the cyclin D–CDK4/6–pRb axis has a significant impact on tumor proliferation and transformation [31]. Here, CDK6 is linked to breast carcinoma.